A Phase 2 Study of Osimertinib for GGN in Lung Cancer

Study Description

Evaluating the Effectiveness of Osimertinib in Suppressing Progression of Ground-Glass Nodules in Lung Cancer Patients with EGFR Mutations

Study Details

Registry ID:

NCT04591002

Conditions:

Lung Cancer

Phase:

Phase 2

Target Enrollment:

43 participants

Start Date:

September 11, 2022

Age Range:

30–75 years

Healthy Volunteers:

No

Study Locations (2 sites)

• SMC
  Seoul, KangnamguKorea, Republic of, Korea, Republic of
• SMC
  Seoul, KangnamguSouth Korea, South Korea

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →